To better understand the evolutionary forces driving HCC, we performed a near-saturating transposon mutagenesis screen in a mouse HBV model of HCC. This screen identified 21 candidate early stage drivers and a very large number (2,860) of candidate later stage drivers that were enriched for genes that are mutated, deregulated or functioning in signaling pathways important for human HCC, with a striking 1,199 genes being linked to cellular metabolic processes. Our study provides a comprehensive overview of the genetic landscape of HCC.
Nearly 500,000 people are diagnosed with HCC each year, and their overall 5-year survival rate is below 12%. The highest incidence of HCC is in regions in which infection with HBV is endemic, and men are two to four times more likely to develop HCC than women. HCC related to infection with HBV has also become the fastest-rising cause of cancer-related death in the United States during the past two decades. Although the use of emerging sequencing and genomics technologies has identified many mutated and/or differentially expressed genes in HCC, these techniques have also uncovered a surprising amount of intratumor and intertumor heterogeneity [1] [2] [3] [4] [5] . For these reasons, and because important DNA mutations can be concealed among the large number of passenger mutations present in these tumors, it has been difficult to identify the complete complement of driver genes for HCC. Epigenetic silencing of tumor suppressor genes also frequently occurs in tumors 6, 7 . This fact, combined with recent studies showing that there may be thousands of haploinsufficient tumor suppressor genes 8 , makes the identification of all driver genes for HCC even more difficult. Published reports from the Encyclopedia of DNA Elements (ENCODE) project have also identified millions of functional elements, many of which are transcription factor binding sites that regulate the expression of genes often located hundreds of kilobases away 9 . Nearly 70% of disease-associated SNPs identified in genome-wide association studies map to these distal enhancers 9 , raising the possibility that noncoding mutations in these distal elements might also substantially contribute to cancer and potentially explaining why some tumors have few or no mutated cancer genes 10, 11 , even after extensive genome characterization. Tumors with a paucity of mutated genes might also have mutations in very infrequently mutated genes that we do not yet have the statistical power to detect.
One method for identifying these missing cancer genes, as well as to validate the hundreds of candidate cancer genes already described, is through comparative genomics involving transposon-based insertional mutagenesis 12 . It has recently become possible to mobilize the Sleeping Beauty (SB) transposon in essentially any mouse tissue at high enough frequencies to induce virtually any kind of cancer [13] [14] [15] . Mutagenic SB transposons carry a strong promoter for activating proto-oncogenes and transcriptional stop cassettes for inactivating tumor suppressor genes, and the transposons therefore tag cancer genes in tumor cells. Human tumor genomes are complex, with multiple operative mutagenic processes. By contrast, transposons tag cancer genes directly, thus facilitating their identification.
Here we sought to obtain a comprehensive list of genes that are functionally necessary to trigger HCC by performing a large-scale SB transposon mutagenesis screen 13, 14 . Because the major etiology of Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model human HCC is chronic infection with HBV 16 , we mobilized SB in the livers (liver-SB) 17 of transgenic mice predisposed to develop HCC as a result of expression of the toxic HBV surface antigen (HBsAg) in their livers (called liver-SB/HBsAg mice) 18 . By using this mouse model, we aimed to identify genes that could cooperate with HBV-induced liver inflammation in the induction of HCC, which is similar to that occurring in most human HCC.
RESULTS

HBV-associated HCC mouse model for mutagenesis screening
Liver-SB/HBsAg transgenic mice develop chronic liver inflammation with associated reactive hyperplasia ( Fig. 1a and Supplementary  Fig. 1 ), hepatocytomegaly and ground glass hepatocytes (Fig. 1b) , similarly to human chronic hepatitis B and the previously characterized HBsAg mice 18 . Liver-SB/HBsAg modifications lead to the appearance of preneoplastic foci, which are visible from 19.7 weeks of age, followed by hepatocellular adenoma and trabecular HCC (Supplementary Fig. 2 ). SB induced a cooperative tumorigenic effect with HBsAg, as liver-SB/HBsAg mice displayed reduced survival (Fig. 1c) . We also noted a tendency toward larger numbers of tumors ( Supplementary Fig. 2 ) and more advanced-stage disease compared to HBsAg mice alone (Fig. 1d) .
To identify the genes mutated by SB that cooperate with HBsAgassociated inflammation in tumor induction, we PCR amplified and sequenced the transposon insertion sites from 250 tumors harvested from 34 mice 19 , which yielded 328,687 sequence reads and identified an average of 1,315 unique transposon insertion sites per tumor. By comparing the location of the transposon insertions in all tumors, we found a few tumors that were genetically related. We removed these tumors, leaving 228 genetically unrelated tumors, which we subsequently used for downstream analysis ( Supplementary  Figs. 3 and 4) .
Large-scale screen identifies common insertion sites
We then screened for common insertion sites (CISs), which are regions in cancer genomes that contain a higher density of transposon insertions than predicted by chance and are therefore likely to contain a cancer gene (CISs on chromosome 1 could not be conclusively identified because of local transposon hopping, and we therefore excluded CISs on this chromosome). A gene-centric CIS-calling method (gCIS) that looks for a higher density of transposon insertions within the coding regions of all RefSeq genes than predicted by chance 20 Table 1a) , whereas a non-gene centric Gaussian kernel convolution (GKC) method 21 that looks for a higher density of insertions within fixed kernel widths of 15-240 kb (ref. 22 ) identified 2,041 CISs containing 2,103 genes (Supplementary Table 1b) . There was an 83% overlap between the CISs identified by these two methods (P < 2 × 10 −16 , χ 2 with Yates correction), and together they identified 2,871 CIS loci containing 2,881 genes (Supplementary Table 1c and Supplementary  Fig. 5a ). In vitro transposition cell culture assays have suggested that SB is a random insertional mutagen and that the only requirement for insertion is a TA dinucleotide 12 . Although the GKC method scans the entire cancer genome for CISs, most CISs were located within or in close proximity to genes, providing additional evidence that SB targets the coding regions of genes that confer a selective advantage for tumor growth. gCISs not identified by GKC often contained very large (>300 kb) or small (<10 kb) genes and were probably missed in part because of the use of fixed kernel widths ( Supplementary Fig. 5b,c) .
identified 2,525 gCIS genes (Supplementary
To estimate the genetic coverage of this screen, we randomly selected subgroups of 10-220 tumors from the 228 total tumors and then used GKC to identify the CISs for each subgroup. We then plotted the number of tumors in each subgroup against the genomic base pairs covered by all the CISs identified for each subgroup. The curve plateaued before reaching 100 tumors, indicating that the screen was approaching saturation with as few as a 100 tumors (Fig. 2a,b) . Adding more tumors merely identified additional CISs of lower frequency ( Supplementary Figs. 6 and 7) . Consistent with this notion of saturation, this screen identified most of the CIS genes found previously in much smaller-scale HCC transposon screens performed in p53 mutant 17 and Sav1-deficient mice (Supplementary Fig. 8 ).
To our knowledge, this is the first saturating transposon screen for cancer genes reported for mice.
Nearly 68% of the CIS genes were mutated in <20% of the tumors, and each tumor contained 387 mutated CIS genes on average (Fig. 2c,d ). These findings are indicative of extensive intratumor The sample shown is from a 20.4-week-old liver-SB/HBsAg male mouse. (c) Kaplan-Meier survival curves for male and female mice of all four combinations of genotypes: liver-SB/HBsAg (SB/HBV), liver-SB (SB), HBsAg transgene (HBV) and littermate control mice carrying an inactive transposon (no transposase) and no HBsAg transgene (control). The median survival for females was 79.1 weeks for liver-SB/HBsAg mice and 103.7 weeks for liver-SB mice (log-rank test P < 10 −4 ). The median survival for males was 70.4 weeks for liver-SB/HBsAg mice, 94.9 weeks for liver-SB mice and 88.4 weeks for HBsAg mice (log-rank test P < 10 −4 ). (d) Summary of histopathology performed on livers of moribund male mice of various phenotypes. We observed more HCC and hepatocellular adenoma (HCA) in the liver-SB/HBsAg class than in the two classes liver-SB and HBsAg combined. Although a trend is visible, it was not significant (P = 0.086, one-sided Fisher's exact test on a contingency table). The overall penetrance for hepatic tumorigenesis in liver-SB/HBV mice was 77%. A r t i c l e s npg A r t i c l e s heterogeneity that likely resulted from branching tumor evolution, similar to that reported for several human cancers 23 , combined with the large mutational load induced by SB. In this HCC model, every liver cell contains ~350 copies of the transposon 13 , which, when induced to transpose, can transpose over and over again. In addition, because the transposon insertion sites are PCR amplified before being deep sequenced, insertional mutations present in a small number of cells in the tumor can be identified. It is this ability to sample the extensive intratumor heterogeneity at such a deep level that we believe made it possible to approach saturation with only 100 tumors.
General features of HCC CIS genes
The transposon 13 contains a promoter that is used to deregulate oncogenes and stop cassettes in both transcriptional orientations to inactivate tumor suppressor genes. Transposon insertions at oncogenes therefore tend to be located at the 5′ end of the gene in the same transcriptional orientation, whereas insertions in tumor suppressor genes are usually located throughout the gene in either orientation. Insertion site patterns are thus often predictive of gene function. For the genes identified here and in other transposon screens performed in solid tumors [13] [14] [15] 17, 19, 22, 24 , the majority are predicted to function as tumor suppressor genes. Most genes also have insertions only in one allele, suggesting that they may function as haploinsufficient tumor suppressor genes, although it remains possible that the other allele is silenced by an epigenetic or other mutational event. This haploinsufficienty is consistent with recent studies performed in human cells and tumors, which identified hundreds of haploinsufficient genes that are able to drive cellular proliferation. These genes are postulated to operate in cooperative networks to maximize proliferative fitness 25 , which supports other studies indicating that even partial inactivation of tumor suppressor genes can contribute to tumorigenesis 8 . Branching tumor evolution complicates efforts to implement personalized medicine and suggests that targeted therapies might be directed to genes that are mutated at the trunk of the evolutionary tree. Transposons provide powerful tools for identifying trunk genes, as insertions in trunk genes are more likely to be associated with a higher number of sequencing reads. Despite the splinkerette PCR method preventing a perfect indication of read quantification, previous studies have shown that CIS genes with high read depth are more likely to be highly penetrant, as is seen with APC 22 . To identify potential trunk genes for HCC, we again screened for CISs, but this time we used only the 25, 197 insertions that were represented by at least four sequencing reads each. Among the 524 CISs identified by this approach ( Supplementary Table 1d ) were 21 outlier CISs that showed the highest sequencing read counts and frequencies of occurrence ( Fig. 2e and Supplementary Fig. 9a (refs. 30,31) ) have known tumor suppressive roles in HCC, and Snd1 has been described as an oncogene that promotes HCC angiogenesis 32, 33 . Two genes (Zbtb20 (refs. 34,35) and Ankrd17 (refs. 36,37) ) are involved in hepatocyte differentiation and maturation, and Zbtb20 is a transcription factor that represses the expression of α-fetoprotein, which is a biomarker widely used for HCC surveillance. The Setd2 tumor suppressor gene 38 and the putative tumor suppressor genes Adk 39 , Dpyd 40, 41 , Kmt2e (also known as Mll5) (ref. 42) and Nfia 43, 44 were also identified as potential driver genes for HCC, although there (Fig. 2e) is the merger of several CISs at the same imprinted locus 52 (Rian, Rtl1 and Sfp865 (also known as 6430526N21Rik) and a micro-RNA cluster), which was targeted in 38.4% of the tumors. The majority (92%) of the transposon insertions at this CIS are located on the negative strand ( Supplementary Fig. 9b ), indicating a potential oncogenic loss of imprinting and transcriptional activation of Rtl1 or one or more of the microRNAs that are located downstream. Notably, these microRNAs are among the most strongly upregulated micro RNAs in mouse and human HCC 53 .
CIS gene comparison with human data and other indications
We next asked whether the 2,881 HCC CIS genes are specific for HCC by comparing them to the genes identified in transposon screens for colorectal cancer (CRC) 22 and pancreatic adenocarcinoma (PDAC) 19, 24 . These comparisons showed that >60% of the HCC CIS genes are also mutated in CRC and PDAC (P < 2 × 10 −16 ) (Supplementary Fig. 10 ). This is not surprising, as many cancer genes are known to function in more than one cancer cell type. HCC CIS genes are also significantly mutated in human HCC, as shown by the very significant overlap with the genes somatically mutated in human HCC identified in two whole-genome HCC sequencing studies 10, 11 and in a genome-wide analysis of HBV integrations 54 ( Table 1 ). In addition, we found a significant enrichment among the genes listed in the Catalogue of Somatic Mutations in Cancer (COSMIC) database, which reports all of the somatic mutations identified in human HCC, and the genes listed in the Cancer Gene Census database, which aims to catalog all of the driver genes in human cancers ( Table 1) . HCC CIS genes thus have important roles in human HCC and provide additional validation for the genes identified in human HCC. The expression of HCC CIS genes is also specifically deregulated in human HCC. Among 2,189 HCC CIS genes contained in a large microarray data set obtained from 223 HBV-positive patients with HCC 4 (Supplementary Fig. 11a ), 45% were significantly deregulated in human HCC (absolute fold change of >1.5 and adjusted P < 0.00001) ( Supplementary Fig. 11b and Supplementary Table 2) compared to 29% misregulated genes on the array that are not CIS genes (P < 2 × 10 −16 ). Differentially expressed HCC CIS genes also displayed significantly lower P values, and more of these genes were upregulated than downregulated, although this difference was not large ( Supplementary Fig. 11c,d) . Comparison of the HCC microarray data with other CIS gene lists from PDAC 19, 24 and CRC 22 screens showed the highest enrichment for HCC CIS genes ( Supplementary Fig. 11e ), indicating better specificity when the data were from the same tumor type. Overall, 42.5% of the HCC CIS genes are mutated or misexpressed in human HCC ( Fig. 3 and Supplementary Table 3 ). We subsequently confirmed the deregulation of 30 HCC CIS genes by realtime PCR using a microfluidic dynamic array containing 18 HBV-positive human tumors and 9 liver-SB/HBsAg tumors ( Supplementary Fig. 11f and Supplementary Table 4 ). The direction of the expression change (upregulated or downregulated) was positively correlated between human and mouse tumors ( Supplementary Fig. 11g ).
Transposons drive HCC through conserved pathways HCC CIS genes are also enriched in the major cancer signaling pathways that are known to be important for human HCC, such as the Ras-Erk (also called Mapk), p53, Akt, Wnt and Tgf-β-Bmp pathways, together with the recently identified hepato-tumor suppressor Hippo pathway 30 (Fig. 4a, Supplementary Table 5 and Supplementary  Fig. 12 ). Another known HCC signaling pathway, Il-6-Stat3, was less enriched, possibly because the tumor microenvironment locally secretes Il-6, thus activating this pathway in hepatocytes. A similar analysis for PDAC 19, 24 and CRC 22 CIS genes showed that many of these signaling pathways are also enriched for mutations in these genes. Notably, the Hippo pathway was more highly mutated in HCC, whereas the Wnt pathway, which is critical for CRC 22 , was more highly mutated in CRC (Supplementary Fig. 12a ). Transposons also prominently targeted the Hippo pathway in tumors generated in a Sav1-deficient background (Online Methods and Supplementary  Table 1e ). Sav1 activates Mst1, which results in the downstream activation of Hippo signaling 55 . Together these results suggest that The enrichment P values were calculated using a two-by-two contingency 
A r t i c l e s
transposon-induced mutations in Hippo pathway genes cooperate with Sav1 deficiency to further deregulate Hippo signaling and are consistent with the results from a transposon screen performed in Apc mutant mice, which identified a large number of CRC CIS genes that targeted the Wnt pathway 22 . Liver-SB/Sav1-deficient mice also developed multiple large liver tumors nearly 2 months earlier than liver-SB/HBsAg mice, providing additional evidence for an oncogenic role for deregulated Hippo signaling in HCC.
HCC CIS genes target metabolic events
When we classified the HCC CIS genes according to their gene ontology, we noticed a striking over-representation of genes that are linked to cellular metabolic processes (P = 1.4 × 10 −60 , 1,199 genes) ( Fig. 4b and Supplementary Table 6 ). We detected a less striking enrichment for metabolic processes for CRC and PDAC CIS genes ( Supplementary Fig. 13 ), whereas most other ontologies, such as transcription or cell cycle, displayed similar enrichments among all three tumor types. When we focused the gene classification on metabolic processes, we found 47 metabolic categories that were targeted by the transposon during HCC tumor development as compared to only 9 and 10 metabolic categories for CRC and PDAC CIS genes, respectively (Supplementary Fig. 14) . When we looked for enrichment for disease genes annotated in Ingenuity Pathway Analysis, we also found a highly significant enrichment for HCC CIS genes in npg metabolic diseases (P = 4 × 10 −6 , 265 genes); genetic association to cancer was also highly evident (P = 6 × 10 −10 , 431 genes). Overall, genes associated with protein, carbohydrate, lipid and nucleic acid metabolism were highly mutated by SB. Several other processes were also targeted, including oxidoreduction and metabolism of ATP, organophosphate, hormones, isoprenoid and vitamins (Supplementary Table 6 ).
To determine whether similar genetic changes occur in human HCC, we measured metabolic gene expression levels in 18 HBVpositive human HCC tumors and 9 liver-SB/HBsAg tumors using quantitative RT-PCR (qRT-PCR). The deregulation of key metabolic genes was positively correlated in these two species, and similar gene expression signatures were found for most genes ( Supplementary  Fig. 15 ). The classification of HCC CIS genes has thus highlighted the importance and specificity of targeting metabolic genes in HCC. The fact that normal hepatocytes display important general metabolic functions that most likely need to be reorganized during malignant transformation may explain the reprogramming by SB of many aspects of hepatocyte metabolism.
Metabolic profiling and mapping of mouse HCC tumors
To better understand how genetic changes in metabolic genes affect hepatic tumor metabolism, we performed nontargeted metabolic profiling on eight food-restricted liver-SB/HBsAg animals. We used chemical derivatization and gas chromatography coupled to time-offlight mass spectrometry (GC/TOFMS) to identify the differences in metabotypes between malignant (tumor mass >3 mm) and adjacent normal liver tissue. We verified the quality of the acquired metabolomics data by principal component analysis (PCA) and partial leastsquares discriminant analysis (PLS-DA) (Supplementary Fig. 16 ). Even with eight matched samples, statistical analyses using t test and Welch test were able to identify 56 annotated metabolites that were significantly changed in tumors compared to normal adjacent tissues (Supplementary Fig. 17) . Consistent with the transposon data, we noticed significant alterations corresponding to specific metabolic pathways. For instance, carbohydrate metabolism was affected through increased levels of glucose and fructose and reduced levels of ribitol, ribonic acid and allonic acid. The levels of several amino acids, including isoleucine, valine, asparagine, tyrosine, methionine, serine, leucine, phenylalanine, threonine and alanine, were also significantly (P < 0.01) downregulated in tumors, which is consistent with data from human tumors 56 . Moreover, we found components of nucleic acids, including ribose, pyridine, uracil and uridine, at higher levels in tumors. We then integrated the genetic (Supplementary Table 1c) , expression 4 and metabolic results (Supplementary Table 7 ) in order to identify potential correlations. We noticed a marked consistency Figure 5 Mapping of genomic and metabonomic data to metabolic pathways disrupted in HCC. To understand the metabolic pathways that are disrupted in HCC at the genetic, mRNA and metabolite levels, we used data from the liver-SB/HBV screen (supplementary table 1c), human expression data 4 70 . This promotes the accumulation and shuttling of glycolytic intermediates such as glucose-6-phosphate (G6P), fructose-6-phosphate (F6P) and fructose-1,6-biphosphate 2 (FBP) to the PP pathway and macromolecular synthesis 69 . Thus, this termination of the glycolysis metabolic pathway, together with dysregulation of Pcx and Pdk1 and Pdk2 (Pdk1/2), would prevent pyruvate from entering the TCA cycle. This would also lead to a truncated TCA cycle and insufficient glucosedependent citrate production. However, most of the TCA-cycle gene products (Idh1, Idh2 (Idh1/2), Sdha, Fh and Ogdh) and corresponding intermediates are upregulated in tumor cells, except for the downregulation of the aconitase gene family (Aco1 and Aco2 (Aco1/2)), suggesting the TCA cycle is at least partially activated. Our results imply an activation of glutaminolysis (Cat2, Gls and Glud1 and Glud2 (Glud1/2)) that converts glutamine to α-ketoglutarate to replenish TCA-cycle intermediates. Effective maintenance of citrate synthesis is possible through reductive carboxylation of glutamine-derived α-ketoglutarate by Idh1/2 (ref. 73 ). These adaptations around glycolysis and the TCA cycle could allow rapid generation of both ATP for bioenergetics and important metabolites for biosynthesis. In addition, the breakdown of citrate by Acly could constitute a primary source of acetyl-CoA (ac-CoA) for fatty acid and lipid synthesis. Moreover, upregulation of Ldha could convert glutamine-derived pyruvate to lactate that is excreted by the Mct4 transporter outside the cells 68 . 
between genetic alterations, mRNA levels and actual amounts of metabolites, suggesting a probable control of metabolic changes by genetic modifications, at least to glycolysis, the tricarboxylic acid (TCA) cycle, glutaminolysis, the pentose phosphate pathway (Fig. 5 ) and redox regulation (Supplementary Fig. 18 ). Collectively these metabolic alterations control bioenergetics, biosynthesis and redox regulation, which are known to optimize tumor cell metabolism for proliferation and survival. We also tested our interpretation of the integrated data using biochemical assays and in vivo live metabolic imaging 57 . We found that intrahepatic lactate dehydrogenase (Ldh), alanine transaminase (Gpt, also known as Alt) and glutaminase (Gls) enzymatic activities were consistently more strongly activated in large hepatic tumors (Supplementary Fig. 19 ), supporting the enhanced conversion of pyruvate to alanine and lactate and the inclusion of glutamine perhaps as an anaplerotic carbon source to supplement the increased metabolic fuel requirement in larger tumors 58 . Metabolic imaging with hyperpolarized pyruvate 57 also showed a major conversion of pyruvate into alanine and lactate (Fig. 6) , whereas its conversion into bicarbonate and other TCA intermediates was unchanged, indicating a shift toward aerobic glycolysis and anabolic processes relative to oxidative phosphorylation. We note, however, that pyruvate is only one of the fuel sources in HCC, and other processes generating ATP, such as lipid catabolism, have indeed been found to be significantly increased in HCC as well 56, 59 . Overall these experimental findings were consistent with our predictions that were based on the integration of multiple data sets.
DISCUSSION
To our knowledge, we report the first saturating transposon screen for any type of cancer. In total, we identified 2,881 genes that were positively selected during HCC development, and 42.5% of these genes were also mutated or transcriptionally altered in human HCC. The human HCC genome contains a large spectrum of mutations, including DNA amplifications, deletions, rearrangements, point mutations and loss of heterozygosity, in addition to epigenetic changes, that together lead to tumor development. This has made it difficult to discriminate between true driver and passenger mutations for HCC 6 . SB mutagenesis thus provides an important comparative genomics tool for identifying and validating the driver genes for HCC. We also found that many genes mutated by SB encode proteins that function in cancer signaling pathways that are known to be important for human HCC. In addition, we found that multiple genes from the same signaling pathway are often mutated in the same tumor. This is consistent with recent reports describing the Darwinian evolutionary processes that are operative in cancer cells 60 Analysis of variance tests were performed for each metabolic flux result. At the false discovery rate (FDR)-corrected significance level of 0.05, no differences between group means were found. However, explicitly testing for a trend by computing Spearman correlation showed that the metabolic flux of pyr→ala significantly increased with tumor size (ρ = 0.51, FDR-corrected P = 0.022). Although a strong trend was also observed for the metabolic flux of pyr→lac, this did not reach statistical significance (ρ = 0.43, FDR-corrected P = 0.052). The number of animals in groups is indicated above each bar. Error bars, s.e.m. npg in different branches of the tumor evolutionary tree because of high selective pressure 62 . These results support the suggestions of others that it might be better to therapeutically target the signaling pathways themselves rather than the individually mutated genes.
HCC is thought to arise from the hepatocyte, a highly differentiated cell that has programmed specialized functions. The transposon screen identified a surprisingly high enrichment for genes that are implicated in metabolic processes. This high enrichment seemed specific for HCC, as it was not found in transposon screens for other types of cancer 15, 19, 22, 63 . One of the major functions of hepatocytes is the control of metabolic homeostasis, including protein synthesis, transformation of carbohydrates and synthesis of cholesterol, bile and phospholipids. Our metabolomics study is also consistent with assays performed using human samples of serum, urine 64, 65 or liver tissue 56, 59, 66 , demonstrating that these metabolic processes are indeed altered in transformed human hepatocytes. Using an integrative approach involving functional genomics and metabolomics, we further mapped the genetic, transcriptomic and metabolomic results to core metabolic processes that are commonly affected in cancer 67 . This approach helped uncover molecular mechanisms that are likely altered in HCC. This disrupted metabolism included the increased uptake of glucose and glutamine, which is implied by the targeting of the membrane transporters Glut1, Glut2 (also known as Slc2a2) and Slc7a2 (also known as Cat2) by SB, in addition to their upregulated expression in human tumors. As human HCC tissues also show elevation of glucose and glutamine levels 66, 68 , our data support that they may be genetically selected sources fueling tumor HCC cell metabolism. We also identified a shift toward aerobic glycolysis and anabolic processes relative to oxidative phosphorylation in liver tumors. We observed similar deregulation of metabolic genes in human HCC, suggesting that anabolic pathways, in conjunction with aerobic glycolysis (Warburg effect) 69 , contribute to the enhanced glucose metabolism in HCC. Notably, recent in vitro studies showed that heterogeneous nuclear ribonucleoproteins could induce alternative splicing and thereby result in a high PKM2-to-PKM1 expression ratio. This change could be important for the promotion of cell proliferation and aerobic glycolysis in tumors 70, 71 . In line with these studies, we found not only that SB targets Hnrnpa1 but also that mouse and human HCCs significantly overexpress this gene proportionally to the expression of PKM2. This finding suggests that glucose is being shunted through the pentose phosphate pathway toward the biosynthesis of molecules, including nucleotides 70 , and supports the increased lactate production (aerobic glycolysis) that we observed in our in vivo metabolic imaging. Tumor cell proliferation diverts citrate toward fatty acid synthesis, as was suggested in the SB screen. Because the TCA cycle is crucial for generating intermediate metabolites to ensure cell viability, anaplerotic pathways must be activated. Indeed, our results show glutaminolysis as one such possible carbon source, with SB mutations in many genes regulating the glutaminolytic pathway 72, 73 .
Metabolic adaptations that are associated with glucose and glutamine pathways in cancerous hepatocytes could also enhance the antioxidant defenses through NADPH-dependent glutathione and thioredoxin systems in order to maintain cellular redox balance. In this way, changes in glucose and glutamine pathways could support three basic needs for dividing tumor cells, namely bioenergetics, biosynthesis and redox regulation. Inhibiting glycolysis and/or glutaminolysis might therefore be effective in restricting liver tumor formation and progression, as has been suggested for other cancer types 74 . Genes identified by our transposon screen have thus provided a broader and deeper understanding of hepatocellular cancer genomics and metabolism, as well as offering potential molecular and targets for cancer therapy, such as in signaling and metabolic pathways.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mice and histology. We used the following alleles to generate a mouse model of HBV-associated hepatocellular carcinoma: HBsAg transgenic 18 , Alb-Cre 75 , T2/Onc2 (6113) 13 or T2Onc3 (12740) and Rosa26-lsl-SB11 (ref. 14) . The resulting cohorts were on a mixed B6.129 genetic background. Alb-Cre/+; T2Onc2/+; Rosa26-lsl-SB11/+; HBsAg/+ mice were used for the SB screen. Alb-Cre/+; T2Onc3/+; Rosa26-lsl-SB11/+; HBsAg/+ mice were used for metabolic imaging. All animals were monitored on a biweekly basis in accordance with Institutional Animal Care and Use Committee of A*STAR guidelines. Mice of both gender were used for experiments unless stated otherwise. Full necropsies were performed. For DNA extraction, liver tumors were measured and snap frozen. For histology, livers were 10% formalin fixed and paraffin embedded. 5-µm sections were processed for haematoxylin and eosin staining or orcein staining. All slides were reviewed by our veterinary pathologist (J.M.W.). Histological classification of hepatic lesions and tumors were as previously reported 18, 76 .
Identification of transposon insertion sites.
Identification of transposon insertion sites was performed using splinkerette PCR to produce barcoded PCR products that were pooled and sequenced on the 454 GS-Titanium (Roche) platform. Reads from sequenced tumors were mapped to the mouse genome assembly NCBI m37 and merged together to identify nonredundant SB insertion sites. Cloning and mapping of the transposon insertion sites were performed as previously described 19, 22 . 328,687 nonredundant insertion sites (Supplementary Data Set) were used to identify CISs using a gene-centric method 20 and a GKC statistical framework method 21 .
GSK method for CIS identification. Any insertions sites on the transposon donor mouse chromosome 1 for tumors derived from T2/Onc2 were excluded from CIS analysis. The likelihood of 'local hopping' of the transposon is increased where the transposon array is located 77 . This phenomenon can substantially increase the background level of transposon insertion events, thereby complicating CIS analysis. 328,687 nonredundant insertion sites were used to identify CISs using a GKC statistical framework 21 . The previous GKC analysis approach 22 was enhanced by using multiple kernel scales (widths of 15,000, 30,000, 50,000, 75,000, 120,000 and 240,000 nucleotides). CISs predicted across multiple scales and overlapping in their genomic locations were clustered together, such that the CIS with the smallest genomic 'footprint' was reported as the representative CIS. For highly significant CISs with narrow spatial distributions of insertion sites, the 15,000 kernel is typically the scale on which CISs are identified. The P value for each CIS was adjusted by chromosome, and a cutoff of P < 0.05 was used.
Pruning genetically similar tumors from the same animals. We initially sequenced 250 tumors from 34 mice and called CISs using the GKC method on all tumors (with a nonstringent P value significance threshold to capture many loci). Using the boundaries of the CIS loci, we obtained genomic positions that defined 2,110 bins on the genome. We scored every tumor for every bin as having an insertion in the bin or not. We computed the Spearman correlation between all tumors and performed hierarchical clustering (complete linkage). When tumors from the same animal clustered together as pairs in the dendrogram, we retained only the tumor that had the largest total number of insertions. The aim of the pruning is to ensure that there is at least a single tumor from another animal that is the most similar to a tumor from a given animal. In theory, pairs of clustered tumors from the same animal can remain after the pruning step if, for example, three tumors originally clustered together and only one was removed. To resolve this problem, the pruning step can be repeated iteratively. After the pruning step, we tested whether the median Spearman correlation between the 228 remaining same-animal tumors and the median Spearman correlation between the non-same animal tumors was statistically significant. If this was not the case, we terminated the pruning process. On our data set, a single pruning round was sufficient. We used the remaining 228 tumor samples further to call CISs with both GKC and gCIS methods.
Analysis of screen saturation. To determine whether the SB screen had reached saturation and, if it had, what number of samples was sufficient to reach saturation, the GKC CIS calls from all 228 samples were analyzed using the ACT software package 78 . ACT considers genomic locations generated by multiple samples for specific biological phenomenon under study (for example, chromatin immunoprecipitation sequencing (ChIP-seq) peaks) to determine the saturation of a screen. The program considers the various combinations in which samples can be added so that the increase in base-pair coverage is a range of values that is based on all the samples. The results can be depicted as a series of box plots showing the increase in base pair coverage, where the box plot at each position n on the x axis shows the coverage values of all combinations of n samples. Box plots that approach a horizontal asymptote indicate that the coverage has reached saturation.
For the GKC CISs generated by all 228 samples, the insertion sites that contributed to CISs were extracted, resulting in a set of approximately 131,000 sites. The insertion sites were then selected per sample, and pseudokernels of 7,500 nucleotides either side of each insertion were applied to mimic GKC kernels of 15,000 nucleotides. Overlapping kernels within each sample were merged into continuous genomic regions. These 228 modified insertion files were then analyzed using ACT. For each combination of samples, the median values and 25th and 75th percentiles were plotted using the ggplot2 visualization package for the R statistical analysis platform. As a control, the 228 samples were reanalyzed where the same number of insertion sites per sample was selected at random across the mouse genome (excluding chromosome 1, the donor chromosome). The pseudo-15,000-nucleotide kernels were applied. Figure 2a shows the saturation plot for all 228 samples, clearly indicating a 'knee' in the profile as the graph asymptotes with an increasing number of samples. Visual inspection of the graph indicates that, below 50 samples, the screen does not appear to have reached saturation. From 100 samples upwards, there appears to be sufficient coverage to report saturation. Conversely, the plot for the randomized samples is virtually a straight line ( Supplementary  Fig. 4a) , indicating no saturation. Although the analysis does not produce a clear-cut asymptote, this is to be expected because of the type of data under consideration. ACT was designed to analyze such data as ChIP-seq arrays for predicting transcription factor binding sites. In these scenarios, ChIP-seq replicates should ideally report the same key binding sites and genomic locations. Hence, across multiple samples, the same locations should be reported. For SB screens, however, although insertions in the same gene will be found from different samples, the locations of the insertion sites will not overlap perfectly, even with the addition of the 15,000 nucleotide pseudokernels. Hence, each sample will introduce new regions such that the overall coverage will continue to increase even if the screen has truly reached a 'saturation' point. Also, not all samples will contribute to all CISs. Different combinations of samples will therefore result in varying coverages, causing the coverage profile not to asymptote perfectly.
Cross-species oncogenomics analysis. Gene expression assays, conducted on 223 HBV-positive human patients diagnosed with HCC, were used to compare tumors and paired nontumor tissues. The microarray data are publicly available 4 and downloadable at the Gene Expression Omnibus (GEO) database with accession number GSE14520. Human hepatocellular carcinoma expression profiles were downloaded from the GEO database (GSE14520). Only the 223 paired samples hybridized to the HG-U133A platform were selected. Then, CEL files were robust multiarray average (RMA) normalized, and differential gene expression between normal and tumor cells was computed using the Affy and limma package implemented in Bioconductor. As a result, adjusted P values (FDR-based P value adjustment according to Benjamini and Hochberg) and fold changes were obtained for each probe set. Our mouse candidate cancer genes were converted to human genes using three different databases of homologous genes (MGI, HomoloGene and Ensembl) [79] [80] [81] . The human genes obtained were then mapped to the list of Affymetrix platform probe sets. For genes detected with more than one probe set, the probe set with best adjusted P value was considered as the gene representative. The threshold of significance used was the absolute value of fold change more than 1.5 and adjusted P < 0.00001.
Smaller-scale liver mutagenesis screen in the Sav1-deficient background. This study was performed in a Sav1-deficient background with Alb-Cre/+; T2Onc2/+; Rosa26-lsl-SB11/+; Sav1 flox/flox animals. The Sav1 conditional npg allele was previously described 30 . A total of 136 large tumors from 31 animals were used for analysis. Most animals were euthanized at 8-9 months of age, when they had multiple large tumors. The protocol for genomic DNA extraction, barcoded amplification and sequencing on an Illumina Hi-Seq2000 platform was previously described 20 . 6,251,915 reads were mapped to the mouse genome (mm9) and filtered when they were represented by very few sequence reads 20 . The gene-centric CIS identification method (gCIS) identified 73 common insertion sites (Supplementary Table 1e) .
Patient samples. Resected tumor samples were obtained from patients undergoing curative resection for HCC (n = 172). Operations took place between 1991 and 2009 at the National Cancer Centre, Singapore. All samples were collected in accordance with the requirements of the local Singapore Ethical Committees, and informed consent was obtained from all subjects. The patient demographics and clinical characteristics have been described in a previous study 82 . Total RNA was isolated using TRIzol (Invitrogen) following the manufacturer's instructions, and the RNA concentration was quantified by NanoDrop (Thermo Scientific). RNA samples were reverse transcribed to cDNA using the SuperScript III cDNA Synthesis Kit (Invitrogen) in 10-µl reactions containing 1 µg total RNA and oligo(dT) primers according to manufacturer's instructions.
Gene expression analysis from patient samples. Specific primers targeting genes of interest were designed using Primer Express software version 3.0. The primer sequences used for specific target amplification (STA preamplification reaction), as well as those used for qRT-PCR, are listed in Supplementary  Table 4 . For the STA reaction, each cDNA sample was preamplified with 200 nM pooled STA primer mix and TaqMan PreAmp Master Mix (Applied Biosystems) in a 5-µl reaction, which was run for 14 cycles according to the manufacturer's protocol. To remove unincorporated primers, each sample was treated with Exonuclease I (ExoI) (Fermentas) after incubation at 37 °C for 30 min. For inactivation, the mix was incubated at 80 °C for 15 min in a second step. At the end of the ExoI treatment, the reactions were diluted 1:5 in Tris-ethylenediaminetetraacetic acid (TE) buffer (pH 8.0) before use for qRT-PCR. The Fluidigm BioMark real-time PCR system and 48.48 Microfluidic Dynamic Arrays were employed for high-throughput qRT-PCR analysis 83 . As the volume per inlet is 5 µl, the 6-µl volume per inlet with overage was prepared. For the samples, 2.7 µl of each STA and ExoI-treated sample were mixed with 20× DNA Binding Dye Sample Loading Reagent (Fluidigm) and 2× SsoFast EvaGreen SuperMix with Low ROX (Bio-Rad). For the gene expression assays, 0.3 µl of mix primer pairs (100 µM) was added with 2× Assay Loading Reagent (Fluidigm) after the addition of 1× TE buffer to a 6 µl volume. Before loading the samples and assays into the inlets, the chip was primed in the NanoFlex 4-IFC Controller. The samples and assays were then loaded into the inlets of the dynamic array. After loading and mixing of the samples and assays into the chip by the IFC Controller, PCR was run with the following reaction conditions: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Global threshold and linear baseline correction were automatically calculated for the entire chip. The melting curve analysis and threshold cycle (Ct) were provided by Fluidigm Real-Time PCR Analysis software version 3. Fold changes in expression of the genes of interest between liver tumors and adjacent nontumor samples were determined using the comparative Ct method 84 following the formula: 2 −∆Ct(tumor) /2 −∆Ct(nontumor) . GUSB and Gusb were used as the internal control genes in the human and mouse samples, respectively. The −∆Ct data obtained from this calculation were then used to generate the heatmap, as well as supervised hierarchical clustering of tumor and adjacent nontumor samples by dChip software. In addition, statistical analysis was performed by a standard t test to identify significant differentially expressed genes (P ≤ 0.05) between the two studied groups for each species.
Pathway and gene ontology analyses. Gene annotation enrichment analyses were completed with DAVID Bioinformatics v6.7 (ref. 85) . The list of all human genes was used as the default background. For gene ontology analyses, GOTERM and PANTHER were used. For pathway analyses, KEGG was selected. We obtained enrichment of genes that display a genetic association with cancer through DAVID using GENETIC_ASSOCIATION_DB_DISEASE and OMIM.
Metabolomics experiments. Chemicals for metabolomics experiments. HPLCgrade chloroform and methanol were purchased from Tedia Company Inc. HPLC-grade toluene was purchased from JT Baker. MSTFA (N-methyl-N-(trimethylsilyl)trifluoroacetamide) with 1% TMCS (trimethylchlorosilane) and methoxyamine hydrochloride in pyridine (MOX) were purchased from Pierce. Urease of Sigma type III, alkane standard mixture (C10 to C40) and sodium sulfate (anhydrous) were obtained from Sigma Aldrich. MilliQ water was obtained from Millipore. All other chemicals were of analytical grade.
Mouse liver tissue sample preparation. Each control and tumor liver tissue was weighed accurately and transferred to labeled 15-ml glass centrifuge tubes. Monophasic extraction solvent consisting of chloroform, methanol and water (2:5:2 (vol/vol/vol)) was added to each sample such that the liver tissue concentration of each sample was 20 mg ml −1 . The tissue-solvent mixtures were homogenized by ultrasonicating at ambient temperature (24-28 °C) for 90 min followed by mill mixing using stainless steel beads for another 15-20 min. The homogenates were centrifuged at 3,000 r.p.m. at ambient temperature for 3 min, and 800 µl of each supernatant was transferred to a clean 15-ml glass tube. Quality-control samples (n = 3) were prepared by pooling equal amounts of supernatant from four control and four tumor mouse liver tissues. These samples were dried under a gentle flow of nitrogen at 50 °C for 60 min in the Turbovap LV (Caliper Life Sciences). 100 µl of toluene (kept anhydrous with sodium sulfate) was added to each of the tissue extracts, vortexed for 1 min and dried at 50 °C for 45 min using Turbovap LV in order to eliminate any trace of water that might interfere with the GC/MS analysis. The dried metabolic extract was derivatized first with 40 µl of MOX (20 mg ml −1 ) at ambient temperature for 16 h. Subsequently, 60 µl of MSTFA with 1% TCMS was added to the mixture and incubated for 30 min at 70 °C to form the trimethylsilyl derivatives. The mixtures were cooled, and 90 µl of each derivatized sample was transferred into a vial and subjected to GC/TOFMS analysis.
GC/TOFMS analysis. The GC/TOFMS of the derivatized liver samples was performed using the Pegasus 4D GC × GC/TOFMS system (LECO Corporation). The chromatography separation was conducted in onedimensional GC mode in which a 30-m DB-1 GC column with an internal diameter of 250 µm and film thickness of 0.25 µm (Agilent Technologies) was used. Helium was used as the carrier gas at a flow rate of 1.5 ml per min. An injection volume of 1 µl was used, and the injector split ratio was set to 1:5. The injector, transfer line and ion source temperatures were maintained at 220, 200 and 250 °C, respectively, throughout each analysis. The oven temperature was programmed at 70 °C for 0.2 min, increased at 10 °C per min to 270 °C, where it was held for 10 min, and then further increased at 40 °C per min to 310 °C, where it was held for 9 min. The MS was operated in electron ionization mode (70 eV), and the detector voltage was set at 1,800 V. Data acquisition was performed in the full scan mode with a mass-to-charge ratio (m/z) of 40-600 and an acquisition rate of 20 spectra s −1 .
Metabolic data preprocessing. Each chromatogram obtained from GC/ TOFMS analysis was processed for baseline correction, noise reduction, smoothing, peak deconvolution, analyte alignment, preliminary analyte identification and area calculation using a data processing method created using ChromaTOF software version 4.21 (LECO Corporation). Only peaks with a signal-to-noise ratio greater than 210 were used for further analysis. The area of each peak was calculated using unique mass. Preliminary metabolite identifications were performed for peaks with a similarity index of more than 60%, and these peaks were assigned putative metabolite identities based on the National Institute of Standards and Technology (NIST) library, the LECO/ Feihn Metabolomics library (LECO Corporation) and internally compiled spectral libraries. The resulting data table subsequent to data preprocessing was then exported to an Excel spreadsheet. For certain samples, missing values in their respective data tables were replaced by either integrating the baseline at retention times for which peaks were confirmed to be missing or manually integrating peaks that were confirmed to have their retention times shifted. The total area normalization for each sample was performed by dividing the integrated area of each analyte by the sum of all peak areas of analytes present in the sample. The normalization aided in correcting variations due to the amount of liver collected, sample preparation and analysis.
Chemometric data analysis. Normalized data were exported to SIMCA-P+ (version 12.0, Umetrics) to perform PCA to identify clustering trends, as well as to detect and exclude outliers. Before PCA analysis, the GC/TOFMS data npg were mean centered and unit-variance scaled. A DModX plot was calculated to check for any outliers. Quality-control samples were also analyzed in the PCA analysis to ensure that the data acquisition for GC/TOFMS metabolic profiling was reproducible for all samples. After an initial overview of the GC/TOFMS data using PCA analysis, the data were subjected to supervised data analysis using PLS-DA, in which a model was built and used to identify marker metabolites that accounted for the differentiation in the two groups consisting of liver tumor tissues and normal matched liver tissues. To validate and investigate overfitting of the data in the PLS-DA model, permutation tests with 100 iterations were carried out using SIMCA-P+. This permutation test compared the goodness of fit of the original model with the goodness of fit of several models that were based on data for which the order of the Y observations were randomly permuted while the X matrix was kept intact.
Marker metabolite screening. The criteria for the selection of marker metabolites were variable importance values (VIP) >1.0 and t test (Welch's correction) P < 0.05. The fold change of each marker metabolite detected within the control and tumor groups was calculated. Fold change values of less than 1 indicated a higher level of marker metabolite in the normal tissue. Hierarchical clustering was performed using algorithms within dChip software according to established methods 86 . Pearson correlation subtracted from unity was used as the distance metric using the centroid linkage method, which provides bounded distances in the range (−2, 2). The significance threshold for function enrichment was P < 0.01.
Ex vivo biochemical enzyme activity assays. For each enzyme activity assay, 100 mg of liver tissue was homogenized in 200 µl of ice-cold 100 mM Tris-HCl buffer and then centrifuged for 10 min at 13,000g to remove insoluble material. All assays were based on a continuous spectrophotometric rate determination. Hepatic ALT, AST (aspartate aminotransferase, also known as SGOT) and GLS enzyme activities were measured with commercially available enzymatic assay kits (Biovision, catalog #752-100, #753-100; Sigma-Aldrich, EC 3.5.1.2).
Magnetic resonance spectroscopy (MRS) and metabolic imaging. This technology is partially described in a recent publication 57 . Pyruvate polarization and dissolution (metabolic imaging). 40 mg of [1-13 C]pyruvic acid (99% carbon-13-labeled, part # 677175, Sigma Aldrich) doped with 15 mM tritylradical (OXO63, GE Healthcare) and 3 µl of gadoterate meglumine (10 mM, Dotarem, Guerbet) was hyperpolarized in a polarizer with 45 min of microwave irradiation. The sample was subsequently dissolved in a pressurized and heated alkaline solution containing 100 mg l −1 ethylenediaminetetraacetic acid to yield a solution of 80 mM hyperpolarized sodium [1-13 C]pyruvate with a polarization of 45% and physiological temperature and pH 87 .
Metabolic flux in the liver measured by hyperpolarized 13 C MRS. Mice were positioned in a 9.4 T horizontal-bore MR scanner interfaced to a DD2 console (Varian Medical Systems) and inserted into a dual-tuned ( 1 H/ 13 C) mouse volume coil (diameter, 39 mm). Correct positioning was confirmed by the acquisition of an axial proton gradient-echo image: echo time/repetition time (TE/TR), 8.0/100.0 ms; matrix size, 128 × 128; field of view (FOV), 30 × 30 mm; slice thickness, 1.0 mm; excitation flip angle, 30°. A respiratory-gated shim was used to reduce the proton line width to approximately 160 Hz. Immediately before injection, a respiratory-gated 13 C MR pulse-acquire spectroscopy sequence was initiated. 250-350 µl (0.5 mmol per kg body weight) of hyperpolarized pyruvate was intravenously injected over 3 s into the anesthetized mouse. To localize signal over the liver, a 4-to 6-mm slice excitation was applied. Sixty individual liver spectra were acquired over 1 min after injection (TR, 1 s; excitation flip angle, 25°; sweep width, 4,000 Hz; acquired points, 2,048; frequency centered on the pyruvate resonance).
MRS data analysis. Liver 13 C MR spectra were analyzed using the AMARES algorithm as implemented in the jMRUI software package. Spectra were baseline and direct-current offset corrected based on the last half of acquired points. Peaks corresponding to [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]bicarbonate were fitted with prior knowledge assuming a Lorentzian line shape, peak frequencies, relative phases and line widths. Quantified peak areas were plotted against time in Excel (Microsoft). The rate of exchange of the 13 C label from the hyperpolarized pyruvate to each of its downstream metabolites was calculated with a kinetic model designed specifically to assess hyperpolarized pyruvate metabolism using the fitted peak areas as input data. The model accounts for many of the variables in the hyperpolarized experiment, including the rate of injection, the initial polarization level of the hyperpolarized pyruvate and the rate of decay of each of the hyperpolarized compounds. First, the change in [1-13 C]pyruvate signal over the 60-s acquisition time was fitted to the integrated [1-13 C]pyruvate peak area data using equation (1) 
